Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
Dublin, May 14, 2026 (GLOBE NEWSWIRE) -- The "Pipeline of CD73 Inhibitors" report has been added to ResearchAndMarkets.com's offering.This competitive intelligence report about CD73 Inhibitors...
-
Data spans seven presentations across both solid tumors and hematologic malignancies, providing updates on the potential benefit these therapies may bring to patients. Data from the elacestrant plus...
-
- Data from Phase 1b/2 trial presented at ESMO Breast Cancer 2026 further validate a biomarker-driven development strategy for evorpacept - - Findings are consistent with previous results from the...
-
- Company Will Discuss Data and Report First Quarter 2026 Financial Results on May 8 - SOUTH SAN FRANCISCO, Calif., April 30, 2026 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. ("ALX Oncology";...
-
Dublin, April 28, 2026 (GLOBE NEWSWIRE) -- The "ESR1 Mutated Metastatic Breast Cancer Market - A Global and Regional Analysis: Focus on Country, 2025-2035" report has been added to ...
-
Management to be Joined by Two Clinical Leaders in the Breast Cancer Field Expected to Complete Enrollment in Ongoing ELAINE-3 Phase 3 Registrational Study of Lasofoxifene in Metastatic Breast...
-
Dublin, April 23, 2026 (GLOBE NEWSWIRE) -- The "Bone Metastasis in Solid Tumors Market - A Global and Regional Analysis: Focus on Country and Region, 2025-2035" report has been added to ...
-
BOTHELL, Wash., April 21, 2026 (GLOBE NEWSWIRE) -- LeonaBio, Inc. (NASDAQ: LONA), a clinical-stage biopharmaceutical company dedicated to the development of novel therapeutics for diseases with high...
-
Wake Radiology UNC Health Rex announces its continued support for Susan G. Komen® by sponsoring the upcoming 2026 Komen Triangle Race for the Cure.
-
Advanced biomaterial device designed for use in lumpectomy surgeries Interim results from the first 25 of 94 patients at 6 months follow upConfirms REGENERA™ is safe and biocompatible as breast tissue...